Novo Nordisk, producer of Wegovy Weight Loss Drug, said on Wednesday that he will cut 9,000 jobs in an attempt to resume growth and defend himself from the intense competition of the American rival Eli Lilly and a wave of generic drugs.
The renovation, which should save 8 billion from Danish crowns (1.25 billion dollars) per year, occurs when Novo Nordisk faces the slowing down of its medicines for obesity and diabetes.
The Danish company has also issued its third profit notice this year, citing 9 billion crowns in non -recurring costs related to renovation.
The weather rise of the new began in the middle of 2021, when Wegovy became the first highly effective drug against obesity approved by the United States, catapulting the company to the top of the European stock market.
But a wave of purchases that has almost doubled his staff in five years has now come out for culatra. The mass layoffs report the number of new employees to the levels of 2024, said Simon Baker, Analyst by Redburn Atlantic.
In July, investors eliminated $ 70 billion from the pharmaceutical market value after the new warned of profits and appointed Mike Doutdar veteran as new CEO.
The shares have decreased by almost 46% from the beginning of the year, bringing its market capitalization to about $ 181 billion, below its peak of about $ 650 billion last year.
Source: Terra
Rose James is a Gossipify movie and series reviewer known for her in-depth analysis and unique perspective on the latest releases. With a background in film studies, she provides engaging and informative reviews, and keeps readers up to date with industry trends and emerging talents.
